Clinical Trial Report – COVID 19 Special Edition

Description

The cataclysm caused by the COVID-19 pandemic has impacted on clinical trials in terms of alternatives for study participants, enhanced operational and financial support for progressively more complex trial protocol designs and greater collaboration among sponsors. Therefore, presented here is a timely summarised report of new candidate antiviral and vaccine therapies undergoing clinical trials worldwide as from the week 4 to 8 May 2020 in the pursuit of gaining regulatory approval for treatment and/or prophylaxis against SARS-CoV-2 coronavirus infection. The purpose of this report is to present accurate and timely information on clinical trials worldwide, in the anticipation that resources for future clinical trials may be better allocated and development costs lowered. All content given in this report is for informational purposes only and does not constitute patient, clinical or financial advice.